GLORIA

GEOMAR Library Ocean Research Information Access

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    CD5–Positive and CD5–Negative Rheumatoid Factor–Secreting B Cells in IgA Nephropathy, Rheumatoid Arthritis and Graves’Disease (1993)
    Oxford, UK : Blackwell Publishing Ltd
    Scandinavian journal of immunology 38 (1993), S. 0 
    Details
    ISSN: 1365-3083
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: The relative contributions of CD5+ and CD5– B–cells in production of rheumatoid factors (RF) was evaluated in polyclonally activated B–cells from patients with IgA nephropathy (IgAN), rheumatoid arthritis (RA) and Graves’ disease (GD). In IgAN and RA, diseases in which RFs are believed to be involved in pathogenesis, there were 10– and 4–fold decreases respectively in CD5+ IgG–RF–secreting B–cells compared with controls. Furthermore, the number of CD5– IgG–RF– and IgA–RF–secreting B–cells were increased 12– and 14–fold in IgAN and 9– and 4–fold in RA. Such abnormalities were not apparent in GD, in which RFs have not been implicated in pathogenesis. These findings are compatible with the concept of CD5+ RF–secreting B–cells normally acting to prevent production of potentially pathogenic RFs by CD5– B–cells. When IgAN or RA patients’ B–cells were activated in the presence of control instead of autologous CD4+ cells, numbers of RF– secreting CD5– B–cells were reduced to the levels seen with control B–cells plus control T–helper cells. Presumably lymphokine secretion profiles of T–helper cells would be important in determining whether CD5+ or CD5– B–cells are activated to secrete RFs, and perhaps therapeutic manipulation of these profiles could restore normal activity of CD5+ B–cells in IgAN and RA.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1365-3083.1993.tb03244.x
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Cholesterol-lowering therapy may retard the progression of diabetic nephropathy (1995)
    Springer
    Diabetologia 38 (1995), S. 604-609 
    Details
    ISSN: 1432-0428
    Keywords: Key words Hypercholesterolaemia ; non-insulin-dependent diabetes mellitus ; nephropathy ; HMG CoA reductase inhibitor ; lipoprotein(a) ; lipids ; lipoproteins.
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary There is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n = 16; mean dose 30.0 ± 12.6 mg/day) or placebo (n = 18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr51-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p 〈 0.001), LDL-cholesterol (p 〈 0.001) and apo B (p 〈 0.01), the reductions at 24 months being 26, 30 and 18 %, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p 〈 0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p 〈 0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p 〈 0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy. [Diabetologia (1995) 38: 604–609]
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001250050326
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Cholesterol-lowering therapy may retard the progression of diabetic nephropathy (1995)
    Springer
    Diabetologia 38 (1995), S. 604-609 
    Details
    ISSN: 1432-0428
    Keywords: Hypercholesterolaemia ; non-insulin-dependent diabetes mellitus ; nephropathy ; HMG CoA reductase inhibitor ; lipoprotein(a) ; lipids ; lipoproteins
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary There is experimental evidence to suggest that hypercholesterolaemia may play a pathogenetic role in progressive glomerular injury. We investigated the effect of cholesterol-lowering therapy on the progression of diabetic nephropathy in 34 patients with non-insulin-dependent diabetes mellitus. Patients were randomly assigned in a single-blind fashion to treatment with either lovastatin, an HMG CoA reductase inhibitor (n=16; mean dose 30.0±12.6 mg/day) or placebo (n=18) for 2 years. Renal function was assessed by serially measuring the serum creatinine, glomerular filtration rate (using Cr51-EDTA), and 24-h urinary protein excretion. Lovastatin treatment was associated with significant reductions in total cholesterol (p〈0.001), LDL-cholesterol (p〈0.001) and apo B (p〈0.01), the reductions at 24 months being 26, 30 and 18%, respectively. Beneficial effects on serum triglyceride, HDL-cholesterol and apo A1 levels were also observed. Lp(a) showed no significant change in both groups. Glomerular filtration rate deteriorated significantly in the placebo group after 24 months (p〈0.025) but showed no significant change in the lovastatin-treated patients. The increase in serum creatinine was statistically significant (p〈0.02) in placebo-treated patients at 12 and 24 months, and in the lovastatin group after 24 months. Twenty-four hour urinary protein excretion increased in both groups (p〈0.05). Lovastatin treatment was not associated with significant elevations in liver or muscle enzymes. We conclude that effective normalisation of hypercholesterolaemia may retard the progression of diabetic nephropathy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00400731
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria (1992)
    Springer
    Pediatric nephrology 6 (1992), S. 355-355 
    Details
    ISSN: 1432-198X
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00869735
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...